key: cord-0763762-gjaadywn authors: Michon, Alain title: Hyaluronic acid soft tissue filler delayed inflammatory reaction following COVID‐19 vaccination – A case report date: 2021-07-01 journal: J Cosmet Dermatol DOI: 10.1111/jocd.14312 sha: 0325b6893ad0babea00504bd636e54306132ff3a doc_id: 763762 cord_uid: gjaadywn BACKGROUND: The use of hyaluronic acid soft tissue fillers in aesthetic medicine exploded in recent years for many reasons, including being relatively safe. Incidence of delayed inflammatory reactions (DIRs) to hyaluronic acid soft tissue fillers range between 0.3% and 4.25%. These reactions are mediated by T‐lymphocytes and can be triggered by flu‐like illnesses, including SARS‐CoV‐2 infection. Vaccination may also induce hypersensitivity. AIM: In this case report, we present two cases of delayed reaction after hyaluronic acid soft tissue filler treatment of the tear trough area and following mRNA vaccination against SARS‐Cov‐2, also known as COVID‐19, months later. PATIENTS: A 39‐year old female who previously had her tear trough area treated with hyaluronic acid soft tissue filler developed swelling days after getting the mRNA Pfizer‐BioNTech COVID‐19 vaccine. Another patient, a 61‐year‐olf female, developed intermittent facial swelling in areas previously treated with hyaluronic acid soft tissue fillers days after receiving her first dose of the mRNA Pfizer‐BioNTech COVID‐19 vaccine. RESULTS: As demonstrated in our case report, vaccination against COVID‐19 may induce DIRs in patients who previously had hyaluronic soft tissue fillers. CONCLUSION: Delayed inflammatory reactions to hyaluronic acid soft tissue fillers are uncommon and usually self‐limited, with frequent spontaneous resolution. However, considering the ongoing pandemic and the worldwide demand for vaccines against COVID‐19, the aesthetic providers should be conscious of the risks posed by the interaction of such vaccines in patients who previously had or seeking hyaluronic acid soft tissue filler injections. Acute type 1 hypersensitivity reactions, occurring within minutes or hours, are immunoglobulin E (IgE)-mediated. Conversely, late-onset or delayed reactions are inflammatory, T-cell lymphocytes responses and may present as tender and erythematous swelling or nodules. [8] [9] [10] Various factors may contribute to HA soft tissue filler delayed reactions, many reporting a flu-like illness before the delayed reactions, including influenza and SARS-CoV-2. 4, 9, 11, 12 The latter is also known as COVID-19. Recently, after an international survey on 106 participants, the global recommendation on COVID-19 vaccines and soft tissue filler reactions, in cooperation with the international society of dermatologic and aesthetic surgery, concluded that there is no evidence for concern of developing soft tissue filler-related reactions following COVID-19 vaccination. 13 In this case report, we will present two patients who presented with a delayed-type inflammatory reaction within days after receiving a first dose of the mRNA Pfizer-BioNTech COVID-19 vaccine. A 39-year old female, physically fit and healthy, and without any medical comorbidities nor allergies, had her tear trough injected with an HA soft tissue filler, Juvéderm Volite (Allergan inc.), in October 2020 by the author for the correction of undereye hollowness. The placement was done in the subdermal plane using a microcannula, 25 G × 38 mm, TSK Steriglide, under proper sterile condition. A total of 0.8 ml of HA filler was injected into her left tear trough and 0.5 ml to her right tear trough in two separate treatment sessions. The procedures were uneventful. In April 2021, 2 days after receiving the first dose of the mRNA Pfizer-BioNTech COVID-19 vaccine, she reported tender, erythematous swelling at her left tear trough area. The patient contacted the author's clinic. On day 1, a selfie-type picture of the reaction was taken for documentation by the patient. (Figure 1 ). She also experienced flu-like illness symptoms, including fatigue, headache, myalgias, and anorexia, which resolved within 4 days. The following day, a complete medical history was taken. There was no history of recent trauma and infection, and she has not been taking any medications. She was well before getting the vaccine. On exam, the left tear trough area was swollen, mildly erythematous, and tender to touch (Figure 2a ). There was no palpable nodule and fluctuant mass. The patient reported that the area was slightly better than the previous day. The facial right side was without abnormalities. A watchful waiting approach was therefore taken. Her adverse reaction resolved spontaneously by day 5 (Figure 2b ) without any intervention. A 61-year-old female patient, physically healthy, without allergies or significant medical history, except for intermittent benign vertigo, Swelling could be on either side of the face, localized primarily at the cheeks and undereye where she had the soft tissue fillers previously injected. We examined her 3 weeks after she had her vaccine, as that day, she experienced left undereye swelling that was worse than the previous episodes and persisted beyond 72 h. The patient did take a photograph using a mobile device for documentation ( Figure 3 ). On exam, the area was soft, mildly tender with definite swelling, but without erythema, nodule or mass ( Figure 4 ). The author decided F I G U R E 1 Patient's own photograph (taken from a mobile device) on day 1 of appearance of signs and symptoms, showing swelling and related Tindall effect over the left tear trough area to dissolve the product with 75 units of hyaluronidase at a concentration of 150 units/ml. She experienced improvement the following day to complete resolution by the time we examined her for a follow-up 48 h after the hyaluronidase injection ( Figure 5 ). She reported no recurrence of swelling until now. Recently, a team of experts defined the duration of delayed inflammatory reactions (DIRs) as reactions occurring after a normal state, 2-4 weeks or longer after injections. 14 Although the experts strongly supported an infectious trigger, viral or bacterial, for many of the cases reported, they rejected the word hypersensitivity for a broader definition and opted for inflammatory. They confirmed other potential triggers of DIRs, including but not limited to previous or recent dental procedures, low-quality products, and improper techniques. Clinically, DIRs after HA filler were defined as discoloration, erythema, localized hardening of tissue, painful nodules, and edema. 14 Hyaluronic acid fillers are nonpermanent and they last on average between 3 and12 months and even longer in some patients. 15, 16 It was recorded by magnetic resonance imaging that soft tissue fillers could be detected as long as 12 years. Notably, most patients denied having soft tissue fillers treatments when the last injections were over 2 years. 17 Recollection difficulties of previous procedures by patients may be an obstacle in diagnosing, reporting, and treating DIRs if they occur. Hence, the need for appropriate documentation and more accessible retrieval of medical information. Furthermore, newer, longer lasting HA fillers with improved cross-linking technologies could potentially be seeds for inflammation and increase the rate of DIRs. DIRs to HA fillers are bothersome for patients and can be challenging for the aesthetic practitioner. However, it is infrequent. Recent literature reports revealed an incidence rate ranging from 0.3% and up to 4.25% for Juvederm Volbella. 4, 8, 18, 19 This raises the possibility that newer family of soft tissue fillers may be more prone to DIRs. Interestingly, the authors of another study noted within a year a lower incidence of 1.0% per patient for Juvederm Volbella and reported no delayed reactions with Juvederm Vollure (also known as Juvederm Volift) and Voluma, also utilizing the vycross technology. Conversely, NASHA technology-made soft tissue fillers have an incidence rate of DIRs reported at 0.3% and hypersensitivity reactions at 0.8%. 8 The full extent of the mechanisms implicated in DIR has yet to be fully elucidated. It can present weeks to months after the procedure, and many cases were shown to have an identifiable immunological trigger. 4, 14 In their prospective chart reviews on 4,702 treatments, nose, throat, and dental infections) or recent dental work, cosmetic procedures, and vaccination. 27 We recommend waiting for 3 weeks after the COVID-19 vaccine before treating patients with soft tissue fillers, as it may take up to 21 days for the peak immune response. 28 Furthermore, it is argued that larger boluses of HA filler may contribute to nodule formation. Hence, as a precautionary measure, it is recommended to inject a smaller volume with every session of HA filler. 4, 29 DIRs are often transient, self-resorbing within days to weeks; thus, intervention is not always necessary. When a nodule is present, small in size (less than 0.5 cm) and without pain, or minimal, a watchful waiting approach is recommended. In contrast, intervention is necessary if nodules are not improving, painful and tender, with edema and erythema. 14 Nodules are often inflammatory in nature, but keeping the possibility of an infection process, including biofilms and atypical organisms, in the differential diagnosis is important. 30 If the presence of a fluctuant mass is noticed, cultures should be sent for aerobic and anaerobic bacterial, mycobacterial, and fungal cultures before treatment. A biopsy can also be performed if there is no resolution following treatment. 4, [30] [31] [32] Imaging and blood test evaluating inflammatory markers like C-reactive protein might be helpful with the diagnosis. 8, 33 As for the treatments of DIRs, antihistamines were found to have limited value. 9, 10 Noninflammatory nodules that are visible may be dissolved with hyaluronidase (HYAL). 7 In more severe cases of DIRs, which intervention to perform first is debatable. Beleznay et al. 4 frequently treated delayed nodules from Juvederm Voluma with oral and or intralesional steroids combined with HYAL injections. They Photographs taken the day the patient presented to the author's clinic, showing persistent infraorbital swelling F I G U R E 5 Photographs taken 48 h after one single injection session of 75 units of hyaluronidase. We can appreciate complete resolution of the swelling believed primarily that these nodules were immune-mediated. However, systemic steroid therapy may also interfere with the immune response necessary to combat an infection or develop adequate immunity, making its role questionable during the current COVID-19 pandemic and large-scale related vaccination. 34 However, It is generally recommended to start with antibiotic treatment, either tetracycline or a macrolide, for 3-6 weeks. 7 Aesthetic practitioners should be mindful of the risks discussed in this case report. Patients seeking HA soft tissue filler must be educated and correctly consented about the risk of DIRs related to COVID-19 infections and vaccines prior to treatment. Further studies are needed, especially with the novel use of ACE-I medication to prevent and treat DIRs related to HA filler and COVID-19. None. The patients gave their written consent for their images to be used for this publication. Ethical approval was not sought for the present manuscript because it was not required. Data sharing not applicable to this article as no datasets were generated or analysed during the current study. Watchful waiting approach. Hyaluronidase intralesional (10 units of hyaluronidase per 0.1 ml of soft tissue filler; can be repeated as needed, wait at least 48 h). Oral prednisone 40 mg daily for 5-7 days (Consider a longer treatment duration with a tapering dose for slowly resolving, or recurring DIRs). A randomized, double-blind, multicenter comparison of the efficacy and tolerability of restylane versus zyplast for the correction of nasolabial folds Delayed-onset nodules secondary to a smooth cohesive 20 mg/ mL hyaluronic acid filler: cause and management Complication management following rejuvenation procedures with hyaluronic acid fillers-an algorithmbased approach Clinical experience with 11,460 ml of a 20-mg/ml, smooth, highly cohesive, viscous hyaluronic acid filler Global approaches to the prevention and management of delayed-onset adverse reactions with hyaluronic acid-based fillers Inflammatory, immune-mediated adverse reactions related to soft tissue dermal fillers Dermal fillers in aesthetics: an overview of adverse events and treatment approaches Late-onset inflammatory response to hyaluronic acid dermal fillers Delayed hypersensitivity reaction to hyaluronic acid dermal filler following influenza-like illness Hypersensitivity reaction to hyaluronic acid dermal filler following novel Coronavirus infection -a case report Global recommendations on covid-19 vaccines and soft tissue filler reactions: a survey-based investigation in cooperation with the International Society for Dermatologic and Aesthetic Surgery (ISDS) Delayed inflammatory reactions to hyaluronic acid fillers: a literature review and proposed treatment algorithm MRI in detecting facial cosmetic injectable fillers Restylane persisting in lower eyelids for 5 years Hyaluronic acid filler longevity and localization: magnetic resonance imaging evidence Resistant and recurrent late reaction to hyaluronic acid-based gel Late-onset inflammatory adverse reactions related to soft tissue filler injections Hyaluronan as an immune regulator in human diseases New classification schemata of hypersensitivity adverse effects after hyaluronic acid injections: pathophysiology, treatment algorithm Hyaluronan fragments act as an endogenous danger signal by engaging TLR2 The role of CD44 in disease pathophysiology and targeted treatment A review of the metabolism of 1,4-butanediol diglycidyl ether-crosslinked hyaluronic acid dermal fillers Immunologic roles of hyaluronan Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin IIinduced cutaneous inflammation Patient factors influencing dermal filler complications: prevention, assessment, and treatment Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series Complications following injection of soft-tissue fillers Relationship between delayed reactions to dermal fillers and biofilms: facts and considerations Soft-tissue filler complications: the important role of biofilms Dermal fillers: pathophysiology, prevention and treatment of complications A problem-oriented approach to nodular complications from hyaluronic acid and calcium hydroxylapatite fillers: classification and recommendations for treatment COVID-19 and the use of immunomodulatory and biologic agents for severe cutaneous disease: An Australian/New Zealand consensus statement The role of the renin-angiotensin system in skin physiology and pathophysiology Infection fatality rate of COVID-19 inferred from seroprevalence data 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study The socio-economic implications of the coronavirus pandemic (COVID-19): a review How to cite this article: Michon A. Hyaluronic acid soft tissue filler delayed inflammatory reaction following COVID-19 vaccination -A case report